Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Genenta Science SpA ADR (GNTA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: GNTA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -11.25% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 72.61M USD | Price to earnings Ratio - | 1Y Target Price 22.5 |
Price to earnings Ratio - | 1Y Target Price 22.5 | ||
Volume (30-day avg) 34409 | Beta 0.71 | 52 Weeks Range 2.20 - 7.28 | Updated Date 04/1/2025 |
52 Weeks Range 2.20 - 7.28 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.53 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -32.84% | Return on Equity (TTM) -54.13% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 58833157 | Price to Sales(TTM) - |
Enterprise Value 58833157 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -11.48 | Shares Outstanding 18289900 | Shares Floating 11226503 |
Shares Outstanding 18289900 | Shares Floating 11226503 | ||
Percent Insiders 39.26 | Percent Institutions 8.23 |
Analyst Ratings
Rating 4 | Target Price 21.32 | Buy 2 | Strong Buy - |
Buy 2 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Genenta Science SpA ADR
Company Overview
History and Background
Genenta Science SpA is a clinical-stage biotechnology company focused on developing hematopoietic stem progenitor cell gene therapy for cancer. Founded in 2014 in Milan, Italy, it's focused on developing new approaches to cancer treatment. It began trading on the Nasdaq in 2021.
Core Business Areas
- Cell & Gene Therapy: Development of cell and gene therapy products for the treatment of cancer, specifically focusing on HSC gene therapy.
Leadership and Structure
The leadership team includes Pierluigi Paracchi (Chairman & CEO), Dr. Luigi Condorelli (Scientific Founder), and other experienced professionals in biotechnology and finance. Genenta Science SpA is headquartered in Milan, Italy.
Top Products and Market Share
Key Offerings
- Temferon: Lead product candidate, a hematopoietic stem cell gene therapy for glioblastoma multiforme (GBM) and other solid tumors. It's in clinical development (Phase 1/2a trial). Market share is currently 0 as it is still in clinical trials. Competitors include companies developing therapies for GBM, such as Northwest Biotherapeutics (NWBO).
Market Dynamics
Industry Overview
The cell and gene therapy industry is experiencing rapid growth, driven by advances in biotechnology and increasing demand for personalized medicine. The cancer therapy market is highly competitive, with numerous companies developing novel treatments.
Positioning
Genenta Science SpA is positioned as an innovator in the field of hematopoietic stem cell gene therapy for cancer. Its competitive advantage lies in its proprietary technology platform and its focus on a specific therapeutic approach.
Total Addressable Market (TAM)
The TAM for cancer therapies, including gene therapies, is estimated to be in the tens of billions of dollars annually. Genenta is positioned to capture a portion of this market through its innovative approach, pending successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform
- Experienced management team
- Focus on a specific therapeutic approach (HSC gene therapy)
- Strong scientific foundation
- Advanced clinical trials
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Early stage clinical development
- Reliance on a single product candidate
- Geographic concentration (Italy)
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Regulatory approvals for Temferon
- Growing market for cell and gene therapies
Threats
- Clinical trial failures
- Competition from other cancer therapies
- Regulatory hurdles
- Intellectual property challenges
- Economic downturn
Competitors and Market Share
Key Competitors
- NWBO
- BMY
- MRTX
Competitive Landscape
Genenta Science SpA competes with both large pharmaceutical companies and smaller biotechnology firms in the cancer therapy market. Its competitive advantage lies in its HSC gene therapy platform and focus on GBM. However, they are earlier stage than larger competitors.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is represented by the advancement of Temferon through clinical trials.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and potential partnerships.
Recent Initiatives: Recent initiatives include the advancement of Temferon into later-stage clinical trials and exploring partnerships with other pharmaceutical companies.
Summary
Genenta Science is a clinical-stage biotechnology firm with a promising gene therapy platform targeting cancer. It faces significant risks due to its early-stage development and limited resources. Successful clinical trials and potential partnerships are crucial for its future growth. Its focus on a niche area of the cancer therapy market gives it a unique positioning, but competition is strong and funding required is significant.
Similar Companies
- NWBO
- BMY
- MRTX
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Invest at your own risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Genenta Science SpA ADR
Exchange NASDAQ | Headquaters Milan, MI, Italy | ||
IPO Launch date 2021-12-15 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.genenta.com |
Full time employees - | Website https://www.genenta.com | ||
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.